Nouveau Nombre d'Actions et de Droits de Vote d'Innate Pharma au 1er Aout 2021
11 août 2021 01h00 HE
|
INNATE PHARMA
Marseille, France, 11 août 2021 (GLOBE NEWSWIRE) -- Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »),...
Number of Shares and Voting Rights of Innate Pharma as of August 1, 2021
11 août 2021 01h00 HE
|
INNATE PHARMA
Marseille, France, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des...
Number of Shares and Voting Rights of Innate Pharma as of July 1, 2021
12 juil. 2021 01h00 HE
|
INNATE PHARMA
MARSEILLE, France, July 12, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des...
Nouveau Nombre d'Actions et de Droits de Vote d'Innate Pharma au 1er Juillet 2021
12 juil. 2021 01h00 HE
|
INNATE PHARMA
Marseille, France, 12 juill. 2021 (GLOBE NEWSWIRE) -- Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »),...
NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF JULY 1, 2021
12 juil. 2021 01h00 HE
|
INNATE PHARMA
Marseille, France, July 12, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des...
RESULTATS DE L’ESSAI DE PHASE 2 FORCE, EVALUANT AVDORALIMAB CHEZ LES PATIENTS ATTEINTS D’UNE PNEUMONIE SEVERE DUE AU COVID-19
06 juil. 2021 01h00 HE
|
INNATE PHARMA
Marseille, France, 06 juill. 2021 (GLOBE NEWSWIRE) -- L’essai clinique indépendant FORCE n’a pas atteint ses objectifs principaux La Société ne poursuivra pas l’évaluation d’avdoralimab dans le...
Update on Avdoralimab Phase 2 FORCE Trial in COVID-19 Patients with Severe Pneumonia
06 juil. 2021 01h00 HE
|
INNATE PHARMA
Marseille, France, July 06, 2021 (GLOBE NEWSWIRE) -- Investigator-sponsored FORCE trial did not meet primary endpoints Company will stop exploring avdoralimab in COVID-19 ...
Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pneumonia
06 juil. 2021 01h00 HE
|
INNATE PHARMA
Investigator-sponsored FORCE trial did not meet primary endpoints Company will stop exploring avdoralimab in COVID-19 Investigator-sponsored avdoralimab clinical trial in inflammation will continue ...
Innate Pharma presents preliminary data from TELLOMAK trial showing clinical response for lacutamab in mycosis fungoides
22 juin 2021 07h00 HE
|
INNATE PHARMA
Marseille, June 22, 2021 (GLOBE NEWSWIRE) -- First data set from TELLOMAK establishes safety, clinical responses and skin improvement in patients with mycosis fungoides that express KIR3DL2 Data...
Innate Pharma Presents Preliminary Data from TELLOMAK Trial Showing Clinical Response for Lacutamab in Mycosis Fungoides
22 juin 2021 07h00 HE
|
INNATE PHARMA
First data set from TELLOMAK establishes safety, clinical responses and skin improvement in patients with mycosis fungoides that express KIR3DL2 Data support continued development of lacutamab for...